Evidence map›Paper›PMID 19124477›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2009

Sampling strategies for tissue microarrays to evaluate biomarkers in ovarian cancer.

Jenny Permuth-Wey, David Boulware, Nikola Valkov, Sandra Livingston, Santo Nicosia, Ji-Hyun Lee, Rebecca Sutphen, Joellen Schildkraut, Steven Narod, Alex Parker and 3 more

Open access · greenAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Assessment of hepatocyte growth factor in ovarian cancer mortality.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2011
    Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Jenny Permuth-WeyH. Lee Moffitt Cancer Center, Tampa, FL, USA.
David Boulware
Nikola Valkov
Sandra Livingston
Santo Nicosia
Ji-Hyun Lee
Rebecca Sutphen
Joellen Schildkraut
Steven Narod
Alex Parker
Domenico Coppola
Thomas Sellers
Tuya Pal
Moffitt Cancer Center · USUniversity of South Florida · USDuke University · USNemours Children's Clinic · USWomen's College Hospital · CA

Funding

Population-Based Analysis of Ovarian Cancer BiomarkersR01CA106414 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI SUTPHEN, REBECCA · 2005 to 2009
$3.0M
Ovarian Cancer and Mismatch Repair DeficiencyR01CA111914 · NCI · H. LEE MOFFITT CANCER CTR &RES INST · PI PAL, TUYA · 2005 to 2009
$2.2M
Clinical Relevance of Mismatch Repair in Ovarian CancerK07CA108987 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI PAL, TUYA · 2006 to 2010
$664k
NCI NIH HHS K07 CA108987NCI NIH HHS K07CA108987NCI NIH HHS R01 CA106414NCI NIH HHS R01 CA111914NCI NIH HHS R01CA111914
6 · The paper itself

Abstract

introductionTissue microarrays (TMA) enable rapid analysis of biomarkers in large-scale studies involving archival tumor specimens, however, their utility in heterogeneous tumors such as ovarian cancer is limited.

methodsIn this study, immunohistochemical analysis was done on TMAs comprised of epithelial ovarian cancer (EOC) to estimate the prevalence of loss of expression of three mismatch repair proteins. TMAs were initially created using cores sampled from the center of donor tissue blocks from 59 EOC cases. Full sections were subsequently created and levels of expression were compared between tissues sampled from the central portion versus the periphery. Follow-up analyses were done by obtaining cores from the periphery of up to five additional donor blocks per case. A linear mixed model for each protein was used to investigate differences between results from the initial and follow-up blocks.

resultsIn the original TMAs created using centrally sampled cores, loss of mismatch repair expression was noted in 17 (29%) of the 59 cases. By comparison, analyses from peripherally sampled cores revealed loss of expression in only 6 of these 17 cases. For each protein, significant differences (P < 0.05) were detected between results from the initial donor block and the majority of the follow-up blocks.

conclusionsOur investigations, based on EOC, suggest that sampling variability in protein expression may result when TMAs are used. Thus, at least for EOC, it is important to preferentially sample from the periphery of tumor blocks where exposure to tissue fixatives is optimal.

Indexed as

AdolescentAdultAgedAged, 80 and overBiomarkersFemaleFloridaHumansImmunohistochemistryLinear ModelsMiddle AgedOligonucleotide Array Sequence AnalysisOvarian NeoplasmsPopulation SurveillanceBiomarkers

Identifiers

PMID19124477
PMCPMC2664171
OpenAlexW2105980005

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.